Institut Catala d'Oncologia L'hospitalet

L'Hospitalet de Llobregat, Barcelona 08908

0 studies enrolling now · 3 studies all time

What they study most

Advanced Cancer, Advanced Malignancies, Carcinoma, Non-Small-Cell Lung, Kidney Neoplasms

Studies at this site

• A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC — Running, not enrolling
• Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies — Completed
• Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer — Completed